XZP-3287 + letrozole + anastrozole

**XZP-3287 + letrozole + anastrozole** is a drug combination under phase III clinical investigation for the treatment of advanced, hormone receptor-positive, HER2-negative breast cancer in postmenopausal women[3][9]. XZP-3287 (bireociclib) is a novel, selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), interfering with cell cycle progression and inhibiting proliferation in HR-positive breast cancer[1][4][5]. Letrozole and anastrozole are nonsteroidal aromatase inhibitors that suppress estrogen synthesis, thereby blocking estrogen-dependent tumor growth. The combination aims to leverage both targeted cell-cycle inhibition and endocrine therapy for synergistic antitumor effects.

Brand names

bireociclib

Other names

bireociclib + letrozole + anastrozole